Xellar Biosystems Raises $50 Million to Expand 3D Bio Intelligence Platform

June 30, 2026
Xellar Biosystems has secured $50 million in Series A and A+ funding to advance its 3D Bio Intelligence platform that integrates organ-on-chip systems, automation, imaging, multi-omics, and AI modeling for drug discovery.

Xellar Biosystems has raised $50 million in Series A and A+ financing to expand its 3D Bio Intelligence platform, announced in a press release. The funding will support the company's integrated technology stack that includes organ-on-chip systems, laboratory automation, high content imaging, multi-omics analysis, and AI based biological modeling.

Xellar's platform combines human organ-on-chip models with automated experimentation and computational intelligence to generate high quality, multi dimensional biological data. This approach aims to replace reliance on animal models by capturing biological processes under realistic conditions, improving understanding of mechanisms, toxicity, and therapeutic responses.

The new capital will be used to expand automated biological data generation, strengthen AI and computational biology teams, and accelerate the development of virtual cell technologies that connect experimental biology with computational modeling. Founded in 2022, Xellar focuses on combining human relevant biological systems with machine intelligence to improve the speed and predictability of drug discovery.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Funding News AI Brief AI Brief (X)

More from: Life Sciences

06/30
One Brooklyn Health Selects hellocare.ai for AI Assisted Virtual Care Across Hospitals
06/30
Ozelle to Present O-Cyte 1 Hematology Analyzer at ADLM 2026
06/29
4DMedical Gains TGA Approval for CT:VQ Lung Imaging in Australia
06/27
RADIN Health Expands Platform to Four More UHS Nevada Hospitals
06/26
UpDoc Receives FDA Clearance for Clinical AI Platform

More from: Funding

06/30
X Square Robot Reaches $2.8 Billion Valuation After Four Funding Rounds
06/30
Straiker Raises $64 Million Series A for AI Agent Security
06/30
GenerativeX Raises $4 Million Series A Led by Nissay Capital
06/30
Parabellum Investments Acquires Crux Informatics to Expand AI Data Infrastructure for Finance
06/27
Quantifind Secures $200 Million Investment Led by Summit Partners

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like